Angiodynamic Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
4analysts covering
FY Revenue (est.)
$337.3Mnext fiscal year
FY EPS (est.)
-$0.27next fiscal year
Monitoring Framework
Key Performance Indicators
Med Tech Segment Net Sales Quarterly37.3MTarget: Sustained double-digit growth (14% to 16% pro forma growth for FY26)
Total Net Sales Quarterly78.4MTarget: $313.5 million to $315.5 million for full year FY26
Adjusted EBITDA Quarterly1.8MTarget: $10.0 million to $12.0 million for full year FY26
Watch Items
- CEO Succession and Leadership TransitionTrigger: Retirement of current CEO Jim Clemmer anticipated during fiscal 2027Action: Monitor the Board's search committee progress and the appointment of a successor to ensure strategic continuity.
- Manufacturing Footprint Consolidation and Restructuring CostsTrigger: Cumulative restructuring charges reaching $33.2 million against an estimated range of $33.4 million to $38.4 millionAction: Track the completion of legacy plant closures and the scaling of outsourced manufacturing to eliminate cash burn by early FY27.
- Tariff and Inflationary Pressures on Gross MarginTrigger: Estimated full-year FY26 tariff impact of $4.0 million to $6.0 millionAction: Evaluate gross margin recovery as manufacturing transitions progress and pricing adjustments take effect.
Research as of 19 Jun 2026